COVID-19 Vaccine Developers Adjust Phase 3 Trial Protocols to Allow Authorized Vaccines

By Sam | December 17, 2020

COVID-19 vaccine developers are faced with an ethical quandary — whether to let phase 3 trial participants become “unblinded” and to receive authorized vaccines as they become available, which could hinder the collection of meaningful trial data.
Source: Drug Industry Daily

Posted in Drug Industry Daily